跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
RYBELSUS - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
RYBELSUS
Authorized
STANDARD
RYBELSUS
Novo Nordisk Canada Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
23cd06adbc24a314
Company
Novo Nordisk Canada Inc
Type
Standard
Approval Details
Approval Id
23cd06adbc24a314
Drug Approval Canada Name
RYBELSUS
Product Name
RYBELSUS
Status
Marketed
Status Date
2020-04-19
Original Market Date
2020-04-19
Din
02497611
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription , Schedule D
Ahfs
68:20.06
Atc Original
A10BJ06 SEMAGLUTIDE
Atc Name
a 10 bj 06
Aig Number
0159870005
Company Name
Novo Nordisk Canada Inc
Company Address
101-2476 Argentia Road, Mississauga, Ontario, Canada, L5N 6M1
Active Ingredients
SEMAGLUTIDE
14 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
23cd06adbc24a314
Type
Standard
Back to Health Canada Approvals